ClinicalTrials.gg
CompletedNCT07118878Updated Nov 21, 2025

A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants

A Phase 1 interventional study of AGMB-129 and Placebo in Fibrostenotic Crohn's Disease, sponsored by Agomab Spain S.L.U.. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Agomab Spain S.L.U. (part of Agomab Therapeutics NV) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 194 studies in Crohn Disease with a site in Belgium — 41 open to participants now, 56 under way, 29 of them phase 3. Crohn Disease · Belgium.

Enrollment
158th of 175
30 · median 211
Started
2025
with 12 others
Phase 1
7 of 194
none open now
Registered
184th of 194
by date

Among the 194 studies in Crohn Disease with a site in Belgium, this one is the 158th largest by enrollment of the 175 interventional ones that give a count, is one of 13 that started in 2025, is one of 7 in phase 1, and was the 184th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

41 of the 194 studies in Crohn Disease with a site in Belgium are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Crohn Disease with a site in Belgium, or all of them as a file.
02

Study summary

In patients with Crohn's disease (CD), fibrosis of the gastrointestinal (GI) tract can result in stricture (stenosis) formation and obstruction of the GI tract, causing obstructive symptoms and often requiring surgical intervention. There are currently no approved therapies for treating fibrostenotic Crohn's disease (FSCD) and therefore, there is an urgent need for safe and effective antifibrotic therapies.

AGMB-129 has shown to be safe in healthy participants with single doses up to 1200 mg and multiple doses up to 200 mg twice daily (BID) for 10 days, and in FSCD patients with multiple doses up to 200 mg BID for 12 weeks.

This Phase 1 study will explore the safety, tolerability, and pharmacokinetics (PK) of other daily doses of AGMB-129 in healthy participants to inform on dose selection (nominal dose and dosing frequency) for subsequent clinical trials.

03

Conditions studied

  • Fibrostenotic Crohn's Disease

Browse trials for

Keywords

  • FSCD
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between 18 and 55 years of age (extremes included), at the time of signing the .
  2. Body weight of at least 50.0 kg for men and 45.0 kg for women, and a between 19.0 and 30.0 kg/m2 (extremes included) at screening.
  3. Male or female

Exclusion criteria

Exclusion Criteria:

  1. Known to AGMB-129 ingredients or history of a significant allergic reaction to AGMB-129 ingredients as determined by the investigator.
  2. Positive serology for or anti- antibodies at screening, or history of hepatitis from any cause except for hepatitis A that was resolved at least 3 months prior to the first administration of study treatment.
  3. History of or a current condition, including a positive test for -1 or HIV-2 antibodies at screening.
  4. Presence or sequelae of gastrointestinal, liver, kidney ( ≤80 mL/min/1.73 m² using the CKD-EPI formula) or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs at screening. Note: Participants who have an eGFR of up to 10% below 80 mL/min/1.73 m2 may be enrolled in the study at the discretion of the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    AGMB-129

    participants will receive a single dose of AGMB-129 (reference cohort) for 7 consecutive days or multiple doses of AGMB-129 (cohort 1, 2, 3) for 7 consecutive days

    Drug: AGMB-129

  • Placebo comparator
    Placebo

    participants will receive a single dose of placebo (reference cohort) for 7 consecutive days or multiple doses of placebo (cohort 1, 2, 3) for 7 consecutive days

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participant with Adverse Events

    To evaluate the safety and tolerability of AGMB-129 in terms of adverse events (AE) at every visit

    Time frame: From enrollment to the end of treatment at 42 days

  2. Number of participant with abnormal Physical examination

    To evaluate the safety and tolerability of AGMB-129 in terms of physical examination at every visit

    Time frame: From enrollment to the end of treatment at 42 days

  3. Number of participant with abnormal Vital signs

    To evaluate the safety and tolerability of AGMB-129 in terms of vital signs

    Time frame: From enrollment to the end of treatment at 42 days

  4. Number of participant with abnormal electrocardiograms (ECGs) parameters

    To evaluate the safety and tolerability of AGMB-129 in terms of abnormal electrocardiograms (ECGs) at every visit

    Time frame: From enrollment to the end of treatment at 42 days

  5. Number of participant with abnormal 2-dimensional (2-D) echocardiography

    To evaluate the safety and tolerability of AGMB-129 in terms of abnormal 2-dimensional (2-D) echocardiography at every visit

    Time frame: From enrollment to the end of treatment at 42 days

  6. Number of participant with abnormal clinical laboratory tests

    To evaluate the safety and tolerability of AGMB-129 in terms of abnormal clinical laboratory parameters at every visit

    Time frame: From enrollment to the end of treatment at 42 days

Secondary outcomes

  1. Plasma levels of AGMB-129

    To characterize the pharmacokinetics (PK) of AGMB-129 by measuring the amount in plasma

    Time frame: From enrollment to the end of treatment at 42 days

  2. Plasma levels of metabolite MET-158

    To characterize the pharmacokinetics (PK) of metabolite MET-158 by measuring the amount in plasma

    Time frame: From enrollment to the end of treatment at 42 days

  3. Plasma levels of metabolite MET-154

    To characterize the pharmacokinetics (PK) of metabolite MET-158 by measuring the amount in plasma

    Time frame: From enrollment to the end of treatment at 42 days

07

Study locations

1 site
  • SGS Belgium
    Edegem, Belgium
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Sep 2025, 1 month.

Of 33 industry-sponsored phase 1 interventional studies under Crohn Disease, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 1 month is below that.

Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Aug 12, 2025
StartActual
Aug 6, 2025
Primary completionActual
Sep 15, 2025
CompletionActual
Sep 15, 2025
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07118878
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Aug 6, 2025
Primary completion
Sep 15, 2025
Completion
Sep 15, 2025
Last update
Nov 21, 2025

Study contacts

Carmen Fleurinck, MD
study director · Agomab Spain SL

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ontunisertib

Start the discussion